Causation
Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells
Cellular Oncology 2026 June 8 [Link] Eleonora Nigliato, Yan Ma, Rita Derua, Maria Butyrin, Sandra P Nunes, Léa Guilmot, Antonio De Gianni, Rüveyda Dok, Andrew P Feld, Michael Ohlmeyer, Brian E Wadzinski, Sandra Nuyts, Ilaria Elia, Anna Sablina, Veerle Janssens Abstract Purpose: Malignant pleural mesothelioma (MPM) is a rare cancer of the pleura, frequently related…
Read MoreMetabolic vulnerabilities in pleural mesothelioma
Oncogenesis 2026 May 20 [Link] Sílvia Plans-Marin, Cristina Muñoz-Pinedo, Ernest Nadal Abstract Mesothelioma is a rare tumour of mesothelial origin that is often diagnosed at advanced stages. Despite recent approval of immunotherapy, the prognosis of mesothelioma remains dismal. Growing evidence links tumour metabolism to the molecular mechanisms driving mesothelioma’s aggressiveness, therapeutic resistance and poor outcomes.…
Read MoreRethinking continuity in general practice for people with incurable illness: a qualitative case study of mesothelioma
The British Journal of General Practice 2026 May 14 [Link] Emilie Couchman, Steph Ejegi-Memeh, Sarah Mitchell, Clare Gardiner Abstract Background: Continuity in general practice has clear benefits but is difficult to achieve. Existing research has identified groups of individuals who may especially benefit from continuity, such as those with a terminal condition. Mesothelioma is an…
Read MoreEpidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma
Lung Cancer 2026 July [Link] Miyu Kano, Aki Furusawa, Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Peter L Choyke, Hisataka Kobayashi Abstract Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer mostly associated with asbestos exposure. Effective treatments are limited, and the prognosis is extremely poor. Therefore, the development of novel therapeutic approaches is…
Read MoreEmerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview
Thoracic Cancer 2026 April [Link] Raffaella Pagliaro, Beatrice Leonardi, Angela Schiattarella, Grazia Bergameo, Carmine Picone, Adolfo Gallipoli D’Errico, Filippo Scialò, Fabio Perrotta, Maria Luisa De Rimini, Alfonso Fiorelli, Andrea Bianco Abstract Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic…
Read MoreA case of delayed recurrence of pleural mesothelioma with intradural invasion
Surgical Neurology International 2026 March 20 [Link] Hidetoshi Sato, Rui Omichi, Yuto Nigami, Nobuyuki Shimokawa Abstract Background: Pleural mesothelioma (PM) is a tumor of the pleural epithelium with a poor prognosis. Asbestos exposure is closely related to its occurrence. To date, there have been 13 reports of PM with intradural invasion. Case description: A 73-year-old male was…
Read MoreClinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study
BMC Cancer 2026 April 2 [Link] Alejandro Avilés-Salas, David Dávila Dupont, Alejandro Aranda-Gutierrez, Andrea Nallely Heredia-Jara, Enrique Caballé-Perez, Luis Cabrera-Miranda, Andrés F Cardona, José Lucio-Lozada, Cesar Castillo-Ruiz, Norma Hernandez-Pedro, Luis Corrales, Claudio Martin, Oscar Arrieta Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited treatment options. Recently, GATA3 has emerged as a useful adjunct immunohistochemical marker, especially for non-epithelioid subtypes. Although…
Read MoreTGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma
International Journal of Molecular Sciences 2026 February 25 [Link] Valeria Ramundo, Maria Luisa Palazzo, Stefania Lignola, Daniela Raimondo, Joanna Kopecka, Elisabetta Aldieri Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor associated with asbestos exposure, which represents a current problem. MPM is characterized by a poor prognosis and an unsatisfactory therapeutic approach. Therefore,…
Read MorePivotal role of long non-coding RNA in the development of new therapeutic approaches for pleural mesothelioma
Discover Oncology 2026 March 12 [Link] Caroline Joseph Kiriacos, Dina M Elkahwagy, Manar Mansour Abstract Pleural mesothelioma is a rare aggressive tumor that affects the parietal layer of the pleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late…
Read MoreGermline genetic testing and privacy concerns in patients with mesothelioma
Genetics in Medicine 2026 March 4 [Link] Owen D Mitchell, Abigail P Sneider, Katie Gilliam, Daniela Del Gaudio, Meghana Gaduraju, Soma Das, Feighanne Hathaway, Darren S Bryan, Sanjukta Tawde, Shelly Galasinski, John Novembre, Anya E R Prince, Jane E Churpek, Hedy L Kindler, Michael W Drazer Abstract Purpose: Mesothelioma, a disease overwhelmingly driven by asbestos…
Read More
Skip to content